Browsing by author "Steain, Megan"
Sort by:
Title A-Z
-
Discovery of Cyclic Peptide Ligands to the SARS-CoV_2 Spike Protein Using mRNA Display
Norman, Alexander; Franck, Charlotte; Christie, Mary; Hawkins, Paige M. E.; Patel, Karishma; Ashhurst, Anneliese S.; Aggarwal, Anupriya; Low, Jason K. K.; Siddiquee, Rezwan; Ashley, Caroline L.; Steain, Megan; Triccas, James A.; Turville, Stuart; Mackay, Joel P.; Passioura, Toby; Payne, Richard J.Published 2021The COVID-19 pandemic, caused by SARS-CoV-2, has led to substantial morbidity, mortality, and disruption globally. Cellular entry of SARS-CoV-2 is mediated by the viral spike protein, and affinity ligands to this surface ...Article -
High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
Counoupas, Claudio; Pino, Paco; Stella, Alberto O.; Ashley, Caroline; Lukeman, Hannah; Bhattacharyya, Nayan D.; Tada, Takuya; Anchisi, Stephanie; Metayer, Charles; Martinis, Jacopo; Aggarwal, Anupriya; Dcosta, Belinda M.; Britton, Warwick J.; Kint, Joeri; Wurm, Maria J.; Landau, Nathaniel R.; Steain, Megan; Turville, Stuart G.; Wurm, Florian M.; David, Sunil A.; Triccas, James A.Published 2022Global control of COVID-19 will require the deployment of vaccines capable of inducing long-term protective immunity against SARS-CoV-2 variants. In this report, we describe an adjuvanted subunit candidate vaccine that ...Article -
Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice
Ashhurst, Anneliese; Johansen, Matt; Maxwell, Joshua; Ashley, Caroline; Aggarwal, Anupriya; Siddiquee, Rezwan; Miemczyk, Stefan; Nguyen, Duc; Mackay, Joel; Counoupas, Claudio; Byrne, Scott; Turville, Stuart; Steain, Megan; Triccas, James; Hansbro, Philip; Payne, Richard; Britton, WarwickPublished 2022Current vaccines against SARS-CoV-2 substantially reduce mortality, but protection against infection is less effective. Enhancing immunity in the respiratory tract, via mucosal vaccination, may provide protection against ...Preprint -
Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens
Counoupas, Claudio; Pino, Paco; Stella, Alberto O.; Ashley, Caroline; Lukeman, Hannah; Bhattacharyya, Nayan D.; Tada, Takuya; Anchisi, Stephanie; Metayer, Charles; Martinis, Jacopo; Aggarwal, Anupriya; Dcosta, Belinda M.; Kint, Joeri; Wurm, Maria J; Landau, Nathaniel R.; Steain, Megan; Turville, Stuart G; Wurm, Florian M; David, Sunil A.; Triccas, James A.Published 2021ABSTRACT Global control of COVID-19 will require the deployment of vaccines capable of inducing long-term protective immunity against SARS-CoV-2 variants. In this report, we describe an adjuvanted subunit candidate vaccine ...Preprint -
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Cromer, Deborah; Steain, Megan; Reynaldi, Arnold; Schlub, Timothy E; Wheatley, Adam K; Juno, Jennifer A; Kent, Stephen J; Triccas, James A; Khoury, David S; Davenport, Miles PPublished 2021Background Several SARS-CoV-2 variants of concern have been identified that partly escape serum neutralisation elicited by current vaccines. Studies have also shown that vaccines demonstrate reduced protection against ...Article -
Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial
Cromer, Deborah; Reynaldi, Arnold; Steain, Megan; Triccas, James A; Davenport, Miles P; Khoury, David SPublished 2021Abstract A recent study analysed the relationship between neutralising antibody response and protection from SARS-CoV-2 infection across eight vaccine platforms 1 . The efficacy results from a phase 2b/3 trial of a ninth ...Preprint -
Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC) trial.
Cromer, Deborah; Reynaldi, Arnold; Steain, Megan; Triccas, James A; Davenport, Miles P; Khoury, David SPublished 2022The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other mRNA vaccines. Here we show that the low efficacy follows from the dose used and the presence of SARS-CoV-2 ...Article -
SARS-CoV-2 variants: levels of neutralisation required for protective immunity
Cromer, Deborah; Steain, Megan; Reynaldi, Arnold; Schlub, Timothy E; Wheatley, Adam K; Juno, Jennifer A; Kent, Stephen J; Triccas, James A; Khoury, David S; Davenport, Miles PPublished 2021Abstract A number of SARS-CoV-2 variants of concern (VOC) have been identified that partially escape serum neutralisation activity elicited by current vaccines. Recent studies have also shown that vaccines demonstrate ...Preprint
Sort by:
Title A-Z